Screen Failure Sample Clauses

Screen Failure. A Screen Failure is a consented Trial Subject who fails to meet the screening visit criteria and is thus not eligible for enrolment into the Trial. .
Sample 1Sample 2
AutoNDA by SimpleDocs
Screen Failure. Screen Failure je Subjekt hodnocení, který již udělil souhlas se zařazením do Studie a který nesplnil kritéria screeningové návštěvy a xxx není způsobilý k zařazení do Studie. . .
Sample 1
Screen Failure. Screen Failure (SF) je Subjekt klinického skúšania, ktorý už udelil súhlas so zaradením do Štúdie a ktorý nesplnil kritériá skríningovej návštevy a tým nie je spôsobilý k zaradeniu do Štúdie. Za Screen Failure náleží platba vo výške 315.30 USD za Subjekt klinického skúšania. Maximálny počet pacientov Screen Failure je 1 zaplatený SF na 1 randomizovaný Subjekt klinického skúšania. 3.
Sample 1
Screen Failure. F. Neúspešné vstupné vyšetrenia: Reimbursement for screen failures (being a Research Participant who began screening at Site but was determined to be ineligible to participate in the Study) will be at the amount indicated on the screening visit of the attached Budget Visit Table, not to exceed one (1) screen failure paid per one (1) Research Participant randomized. To be eligible for reimbursement of screening visit completed screening CRF pages must be submitted to IQVIA and any additional information, which may be requested by IQVIA to appropriately document the Research Participant screening procedures. Úhrady za neúspešné vstupné vyšetrenia (za účastníkov výskumu, ktorí začnú vstupné vyšetrenia na pracovisku skúšania, nesplnia však podmienky účasti na skúšaní) sa budú poukazovať v sumách uvedených za vstupnú návštevu v pripojenej tabuľke rozpočtu podľa návštev, pričom ich počet nesmie presiahnuť 1 (jedny) uhradené neúspešné vstupné vyšetrenia na (1) randomizovaného účastníka výskumu. Aby vznikol nárok na úhradu za vstupnú návštevu, je potrebné zaslať spoločnosti IQVIA vyplnené stránky CRF zo vstupných vyšetrení a všetky ďalšie informácie, ktoré môže spoločnosť IQVIA požadovať, aby náležite zdokumentovala vstupné vyšetrenia účastníka výskumu.
Sample 1
Screen Failure. In case of screening failure, the Visit 1-Screening fee and applicable specific procedure costs will be paid in accordance with sections 1.1 and 1.2 of this Exhibit A for the visit and the procedures performed in accordance with the Protocol. Fees are inclusive of overhead. Idorsia reserves the right to reasonably limit the number of screening failures payments by notifying previously IN WRITING the Institution and the Investigator. 1.6
Sample 1
Screen Failure. Screen failures are defined as individuals who consent to participate in the clinical study but are not subsequently randomly assigned to the study treatment. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any AEs and SAEs. Retesting of abnormal laboratory parameters can be done during the initial screening period at the discretion of the investigator in consultation with the Sponsor’s Medical Monitor (or designee). Subjects who are not enrolled into the study can be rescreened for inclusion in the study one additional time. These subjects will be assigned a new screening number; such subjects will be determined a permanent screen failure after the second screening determines the subject is ineligible.
Sample 1
Screen Failure. A Screen Failure shall be defined as a Study Participant who has signed an Informed Consent but could not be effectively included in the Study under the inclusion/exclusion criteria or for other reasons. A maximum of X Screen Failure shall be paid during the study at a rate of XXXXX per Screen Failure Subject. Pacienti, kteří neprojdou vstupními vyšetřeními: Pacienti, kteří neprojdou vstupními vyšetřeními, budou definováni jako účastníci studie, kteří podepsali informovaný souhlas, ale nebylo možné je skutečně zařadit podle zařazovacích/vylučovacích kritérií nebo z jiných důvodů. V rámci studie bude proplacen maximálně X pacient, který neprojde vstupními vyšetřeními, a to ve výši XXXXX za pacienta, který neprojde vstupními vyšetřeními.
Sample 1
AutoNDA by SimpleDocs

Related to Screen Failure

  • Payment Failure Any Credit Party (i) fails to pay any principal when due under this Agreement or (ii) fails to pay, within three Business Days of when due, any other amount due under this Agreement or any other Credit Document, including payments of interest, fees, reimbursements, and indemnifications;

  • Equipment Failures In the event of equipment failures beyond the Administrator's control, the Administrator shall take reasonable and prompt steps to minimize service interruptions but shall have no liability with respect thereto. The Administrator shall develop and maintain a plan for recovery from equipment failures which may include contractual arrangements with appropriate parties making reasonable provision for emergency use of electronic data processing equipment to the extent appropriate equipment is available.

  • Power Failure Power Failure means the failure of power or other utility service if the failure takes place off the "residence premises". But if the failure results in a loss, from a Peril Insured Against on the "residence premises", we will pay for the loss caused by that peril.

  • Epidemic Failure Warranty Supplier warrants all Products against Epidemic Failure for a period of three years after DXC’s Acceptance. Epidemic Failure means the occurrence of the same failure, defect, or non-conformity with an Order in 2% or more of Products within any three-month period.

  • Borrower’s Failure to Notify If the Borrower fails to give notice pursuant to Section 1.6(a) above of the continuation or conversion of any outstanding principal amount of a Borrowing of Eurodollar Loans before the last day of its then current Interest Period within the period required by Section 1.6(a) and such Borrowing is not prepaid in accordance with Section 1.8(a), the Borrower shall be deemed to have given the notice three (3) Business Days prior to the end of the then current Interest Period and such Borrowing shall automatically be continued as a Borrowing of a Eurodollar Loan with a one (1) month Interest Period; provided that all Lenders are able to accommodate such one (1) month Interest Period and such Eurodollar Loan shall be subject to the funding indemnity set forth in Section 1.11 hereof in the event it is prepaid prior to the end of the Interest Period. In the event the Borrower fails to give notice pursuant to Section 1.6(a) above of a Borrowing equal to the amount of a Reimbursement Obligation and has not notified the Administrative Agent by 12:00 noon (Chicago time) on the day such Reimbursement Obligation becomes due that it intends to repay such Reimbursement Obligation through funds not borrowed under this Agreement, the Borrower shall be deemed to have requested a Borrowing of Base Rate Loans under the Revolving Credit (or at the option of the Swing Line Lender under the Swing Line) on such day in the amount of the Reimbursement Obligation then due, which Borrowing shall be applied to pay the Reimbursement Obligation then due.

  • Lenders’ Failure to Perform All Advances (other than Swing Loans and Agent Advances) shall be made by the Lenders contemporaneously and in accordance with their Pro Rata Shares. It is understood that (i) no Lender shall be responsible for any failure by any other Lender to perform its obligation to make any Advance (or other extension of credit) hereunder, nor shall any Commitment of any Lender be increased or decreased as a result of any failure by any other Lender to perform its obligations hereunder, and (ii) no failure by any Lender to perform its obligations hereunder shall excuse any other Lender from its obligations hereunder.

  • Epidemic Failure Remedy If an Epidemic Failure occurs, all costs, including but not limited to, replacement Products, parts, upgrades, materials, labor, transportation and inventory replacement arising from an Epidemic Failure shall be borne by Supplier, regardless of whether DXC initiates a field stocking recall or customer-based recall or retrofit, including Products in distributor inventory and DXC’s installed base. Supplier, at its expense, will ensure that such Products, parts or upgrades have the highest shipping priority. DXC reserves the right to procure, upon terms it deems appropriate, similar products to substitute the affected Products, and Supplier shall promptly reimburse DXC for all costs, charges, prices and fees paid in purchasing the substitute products.

  • No Failure to Cure Default The Seller has not received a written notice of default of any senior mortgage loan related to the Mortgaged Property which has not been cured;

  • Company’s Failure to Timely Convert If within two (2) Trading Days after the Company's receipt of the facsimile or email copy of a Conversion Notice the Company shall fail to issue and deliver to Holder via “DWAC/FAST” electronic transfer the number of shares of Common Stock to which the Holder is entitled upon such holder's conversion of any Conversion Amount (a "Conversion Failure"), the Original Principal Amount of the Note shall increase by $2,000 per day until the Company issues and delivers a certificate to the Holder or credit the Holder's balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon such holder's conversion of any Conversion Amount (under Holder’s and Company’s expectation that any damages will tack back to the Issuance Date). Company will not be subject to any penalties once its transfer agent processes the shares to the DWAC system. If the Company fails to deliver shares in accordance with the timeframe stated in this Section, resulting in a Conversion Failure, the Holder, at any time prior to selling all of those shares, may rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Outstanding Balance with the rescinded conversion shares returned to the Company (under Xxxxxx’s and Company’s expectations that any returned conversion amounts will tack back to the original date of the Note).

  • Company’s Failure to Timely Deliver Securities If the Company shall fail, for any reason or for no reason, to issue to the Holder within three (3) Trading Days after receipt of the applicable Exercise Notice, a certificate for the number of Warrant Shares to which the Holder is entitled (or, at the option of the Holders, a book-entry confirmation of the issuance of such Warrant Shares) and register such Warrant Shares on the Company’s share register, the Holder will have the right to rescind such exercise. In addition to any other rights available to the Holder, if the Company shall fail, for any reason or for no reason, to issue to the Holder within three (3) Trading Days after receipt of the applicable Exercise Notice, a certificate for the number of Warrant Shares to which the Holder is entitled (or, at the option of the Holders, a book-entry confirmation of the issuance of such Warrant Shares) and register such Warrant Shares on the Company’s share register and if on or after such third (3rd) Trading Day the Holder (or any other Person in respect, or on behalf, of the Holder) purchases (in an open market transaction or otherwise) Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of Warrant Shares, or a sale of a number of Warrant Shares equal to all or any portion of the number of Warrant Shares, issuable upon such exercise that the Holder so anticipated receiving from the Company, then, in addition to all other remedies available to the Holder, the Company shall, within three (3) Business Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including reasonable brokerage commissions and other reasonable out-of-pocket expenses, if any) for the Warrant Shares so purchased (including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the “Buy-In Price”), at which point the Company’s obligation to so issue and deliver such certificate or credit the Holder’s balance account with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise hereunder (as the case may be) (and to issue such Warrant Shares) shall terminate, or (ii) promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such Warrant Shares or credit the Holder’s balance account with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of Warrant Shares multiplied by (B) the lowest Closing Sale Price of the Common Stock on any Trading Day during the period commencing on the date of the applicable Exercise Notice and ending on the date of such issuance and payment under this clause (ii).

Time is Money Join Law Insider Premium to draft better contracts faster.